Therapeutic Blocking of VEGF Binding to Neuropilin-2 Diminishes PD-L1 Expression to Activate Antitumor Immunity in Prostate Cancer

Investigators reported that neuropilin-2, which functioned as a vascular endothelial growth factor (VEGF) receptor on tumor cells, was an attractive target to activate antitumor immunity in prostate cancer.